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Summary
Background Through a comprehensive analysis of Italy’s estimates from the Global Burden of Diseases, Injuries, and 
Risk Factors Study (GBD) 2017, we aimed to understand the patterns of health loss and response of the health-care 
system, and offer evidence-based policy indications in light of the demographic transition and government health 
spending in the country.
Methods Estimates for Italy were extracted from GBD 2017. Data on Italy are presented for 1990 and 2017, on 
prevalence, causes of death, years of life lost, years lived with disability, disability-adjusted life-years (DALYs), life 
expectancy at birth and at age 65 years, healthy life expectancy, and Healthcare Access and Quality (HAQ) Index. 
We compared the estimates for Italy with those of 15 other western European countries.
Findings The quality of the universal health system and healthy behaviours contribute to favourable overall health, 
even in comparison with other western European countries. In 2017, life expectancy and HAQ Index score in Italy 
were among the highest globally, with life expectancy at birth reaching 85·3 years for females and 80·8 for males in 
2017, ranking Italy eighth globally for females and sixth for males, and an HAQ Index score of 94·9 in 2016 compared 
with 81·54 in 1990, keeping Italy ranked as ninth globally. Between 1990 and 2017 age-standardised death rates for 
cardiovascular diseases decreased by 53·7% (95% uncertainty interval –56·1 to –51·4), for neoplasms decreased by 
28·2% (–32·3 to –24·6), and for transport injuries decreased by 62·1% (–64·6 to –59·2). However, population ageing 
is causing an increase in the burden of specific diseases, such as Alzheimer’s disease and other dementias (DALYs 
increased by 77·9% [68·4 to 87·2]) and pancreatic (DALYs increased by 39·7% [28·4 to 51·7]) and uterine cancers 
(DALYs increased by 164·7% [129·7 to 202·5]). Behavioural risk factors, which are potentially modifiable, still have a 
strong effect, particularly on cardiovascular diseases and neoplasms. For instance, in 2017, 44 400 (41 200 to 47 800)
cancer deaths were attributed to smoking, 12 000 (9600 to 14 800) to alcohol use, and 9500 (5400 to 14 200) to high 
body-mass index, while 47 000 (31 100 to 65 700) deaths due to cardiovascular diseases could be attributed to high LDL 
cholesterol, 28 700 (19 700 to 38 500) to diets low in whole grains, and 15 900 (8500 to 24 900) to low physical activity.
Interpretation Italy provides an interesting example of the results that can be achieved by a mix of relatively healthy 
lifestyles and a universal health system. Two main issues require attention, population ageing and gradual decrease 
of public health financing, which both pose several challenges to the future of Italy’s health status. Our findings 
should be useful to Italy’s policy makers and health system experts elsewhere.
Funding Bill & Melinda Gates Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
In 2015, according to the Organisation for Economic Co-
operation and Development, life expectancy at birth in Italy 
was 82·7 years, the fourth highest globally and the second 
highest in the EU after Spain—approximately 2 years more 
than the average in the 28 countries that comprise the EU.1 
In Italy, life expectancy at birth increased by 2·8 years 
between 2000 and 2015, and in 2015, 9·1% of the gross 
domestic product (GDP) went to health expenditures, a per 
capita expenditure below the EU average.1
Based on these data, Italy’s overall health-care system 
performance appears quite satisfactory and was ranked 
second globally by WHO in 2010,2 first by the Bloomberg 
Global Health Index 2013,3 and ninth in the Global Burden 
of Diseases, Injuries, and Risk Factors Study (GBD) 2016 
Healthcare Access and Quality (HAQ) Index globally.4
Since 1978, when the government established the 
Servizio Sanitario Nazionale—the Italian National Health 
Service (NHS)—Italy’s health-care system has ensured 
universal coverage, free of charge at the point of service, 
for primary, secondary and tertiary care.5 Surgeries 
and treatment in hospital are provided for all citizens 
regardless of their income. Prescription drugs, specialist 
visits, and diagnostic tests are provided for free if pre-
scribed by a physician, and require a copayment based on 
the medicine type and the patient’s status—eg, people 
suffering from chronic diseases, older people (aged 
>65 years), people with a low income, pregnant women, 
and children are exempt from paying for drugs and 
laboratory examinations.6, 7
The system is strongly decentralised, with 19 regions 
and two autonomous provinces given large autonomy in 
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managing health services, while the central government 
is still responsible for the overall system structure and 
guidelines on services that should be provided (ie, 
minimum assistance levels).8
Waiting times are usually up to a few months in public 
facilities, and up to a few weeks in publicly regulated 
private facilities. To shorten waiting time or gain access 
to a specific specialist, patients can opt for the private 
health care, provided by both public and private hospitals, 
which is paid for completely by the patient.9
Cost-containment measures have been progressively 
introduced by central and regional governments in Italy, 
with some acceleration over the past decade. In response 
to national targets to transform part of acute care into long-
term care facilities for chronic conditions, the number of 
hospital beds has decreased substantially, from 4·7 per 
1000 people in 2000, to 3·0 per 1000 people in 2016.10
A spending review in 2012 led to decreased funding for 
the NHS, with respect to the requirements established 
by the State-Regions Conference, of €0·9 billion in 
2012, €1·8 billion in 2013, and €2·0 billion in 2014, re-
presenting reductions of the required funding of 0·8% 
in 2012, 1·6% in 2013, and 1·8% in 2014.11 As a 
consequence of the economic crisis, which caused a 
decrease in GDP of over 8% between 2008 and 2015, the 
public financing of the health systems was further 
reduced.12
The 2018 Economic and Financial Document set public 
health spending as 6·4% of GDP in 2019 and 6·3% of 
GDP in 2020.13 In 2015, for the first time in 15 years, 
a reduction was seen in life expectancy in Italy, with 
female life expectancy decreasing from 85·6 years in 2014 to 
84·9 years, and male life expectancy decreasing from 
80·7 years in 2014 to 80·3 years;14 such reductions were 
fortunately limited to 2015.
To understand the patterns of disease burden and 
examine the response of the health-care system to this 
burden, we provide a thorough description and analysis 
of Italy’s GBD 2017 estimates, including temporal trends 
and comparisons with other countries for the main GBD 
measures.
Methods
Overview
We extracted estimates on Italy and other European 
countries from GBD 2017. Methods for the generation of 
GBD 2017 estimates are described in detail elsewhere15–19 
and are compliant with the Guidelines for Accurate and 
Transparent Health Estimates Reporting.20 GBD 2017 
comprehensively and systematically analysed 282 causes 
of death, 359 diseases and injuries, and 84 behavioural, 
metabolic, and environmental and occupational risks for 
195 countries and territories, including Italy and all 
European countries.
Mortality-related models (all-cause mortality, cause-
specific mortality, and years of life lost [YLLs]) were 
informed by vital registration, sample registration, 
surveys, surveillance, registries, and verbal autopsy data. 
Estimates were generated using standardised approaches 
of data identification, extraction, and processing to 
address issues of incompleteness, variation in classi-
fication systems, and coding practices.15–19
GBD measures
We present data on Italy for 1990 and 2017, including 
prevalence data, causes of death, YLLs, years lived with 
disability (YLDs), disability-adjusted life-years (DALYs), 
life expectancy at birth and at 60 years old, and healthy 
life expectancy (HALE).15–19 Briefly, YLLs are years of life 
lost due to premature death, calculated as the difference 
between the corresponding standard life expectancy 
for that person’s age and sex, and the age of actual death.15
YLDs, described in detail in the GBD 2017 incidence 
and prevalence capstone paper,16 are years lived with 
disability (in which the disability equates to a fraction of a 
year lived in full health) and are the product of the mean 
duration of the condition in years and the disability 
weight of that condition.
Research in context
Evidence before this study
Italy has a universal health care system, good indicators for 
quality of life, and life expectancy in the country is ranked 
among the highest in the world, both for men and women. 
Economic data, however, tell us that government health 
expenditure is shrinking, the number of families in poverty is 
increasing, and the mean age of the population has increased 
substantially in the past 15 years. The aim of our study was to 
gain further insight into Italy’s health performance.
Added value of this study
This is the first analysis of Italy using Global Burden of Diseases, 
Injuries, and Risk Factors Study (GBD) estimates. We used 
GBD 2017 estimates to do a detailed analysis of the main causes 
of disability and premature death and attributable risk factors. 
The estimates also provide an evidence base for analysis of 
crucial aspects of the health system, which to date has relied on 
a generally healthy population and now faces major challenges.
Implications of all the available evidence
Despite a general improvement of the population health status 
when considering age-standardised metrics, population ageing 
has a substantial bearing on the current burden of disease. 
Additionally, a considerable proportion of the burden of disease 
can still be attributed to behavioural risk factors, which could be 
addressed with awareness and prevention policies. The steady 
decrease in public health financing, accompanied by the 
increasing mean age of the population, poses new challenges 
that need to be addressed effectively.
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DALYs are the sum of YLLs and YLDs, and represent 
the loss in years due to premature death and the fraction 
of years lived in less than full health.
The HAQ Index is a GBD measure which relies on 
GBD 2016 estimates, and has not yet been issued for 
2017.4 It is based on mortality-to-incidence ratios from 
causes that, in the presence of quality health care, should 
not result in death.
We also present estimates of infant and under-5 
mortality, which are key epidemiological indicators of 
wellbeing.
In this analysis, data on health financing, including 
government and out-of-pocket spending, was taken from 
the GBD analysis on financing global health, 2016, pre-
senting estimates up to 2015.21
Data extraction and presentation
Data visualisation tools, from which most of the data were 
extracted, are available online and provide data from 
1990 to 2017. We extracted Italy’s financial data from the 
Financing Global Health project.21 We present results for 
the time period between 1990 and 2017. We present 
count estimates, all-age rates per 100 000 population, age-
standardised rates per 100 000 population, and percentage 
changes from 1990 to 2017 for YLDs, YLLs, DALYs, and 
deaths.
GBD causes hierarchy
In GBD 2017, diseases and injuries and causes of death, 
were aggregated in three Level 1 causes (communicable, 
maternal, neonatal, and nutritional conditions; non-
communicable diseases; and injuries), 22 Level 2 causes, 
169 Level 3 causes, and 293 Level 4 causes.15–17,19 For example, 
migraine is a Level 4 cause in the Level 3 headache disorders 
group in the Level 2 neurological disorders group, and in 
the Level 1 non-communicable diseases group. Only the 
top 20 causes of YLDs, YLLs, DALYs, and deaths are 
presented in our analysis.
In the Results section, we used the Level 3 cause 
categorisation, unless otherwise specified. The 84 risk 
factors are aggregated in three Level 1 groups (metabolic, 
environmental and occupational, and behavioural risks), 
19 Level 2 groups, 50 Level 3 groups, and 67 Level 4 
groups.18 We used Level 2 aggregation of risk factors in the 
comparison among selected European countries, and the 
top 20 Level 3 risk factors for other anlyses.
Comparisons with European countries
The European countries we selected for comparison with 
Italy were Austria, Belgium, Denmark, Finland, France, 
Germany, Greece, Ireland, Luxembourg, the Netherlands, 
Portugal, Spain, Sweden, and the UK. These countries 
form the EU15 countries together with Italy and we chose 
them as our comparator countries because they are 
founding members of the EU or have joined the EU (no 
later than 1995). We compared the rankings of each 
country in 2017 by age-standardised YLDs and DALYs, by 
risk factors attributed to DALYs, and by age-standardised 
rates of death, YLLs, YLDs, and DALYs both in 1990 
and 2017.
Socio-demographic Index
We present some estimates for Italy in comparison with 
expected values corresponding to the level of the Socio-
demographic Index (SDI), a composite indicator of 
development status built as geometric mean of 0 to 1 indices 
of total fertility rate in women younger than 25 years, 
mean education for the population aged 15 years and older, 
and lag-distributed income per capita.
Uncertainty analysis
All data are presented with 95% uncertainty intervals 
(UIs),15–19 some of which were specifically extracted for 
the scope of this Article by the Institute for Health 
Metrics and Evaluation (IHME). Differences in median 
percentage changes were considered significant if 
95% UIs did not overlap.
Role of the funding source
The funder of the study had no role in study design, data 
collection, analysis and interpretation, or writing of the 
report. The corresponding author had full access to all 
the data in the study and had final responsibility 
to submit for publication.
Results
In terms of SDI, Italy is ranked 28th globally according 
to GBD 2017, with an SDI value of 0·8434; ranking 
lower than Poland (ranked 27th; 0·8438) and higher 
than the UK (ranked 29th; 0·8431). Life expectancy at 
birth reached 85·3 years for females and 80·8 for males 
in 2017, which ranks Italy eighth globally for females 
and sixth for males. Life expectancy at birth in Italy is 
4 years higher than expected on the basis of its SDI 
value (these estimates are available on the GBD 
Compare website).
Italy’s total fertility rate (ie, number of children born or 
likely to be born to a woman in her life time) has 
remained stable since 1990 and was 1·3 in 2017, which 
was the tenth lowest total fertility rate globally. The 
country’s population remained relatively stable from 
1990 to 2017, with a population increase of just 3·8 million 
(56·8 million [95% UI 52·8–60·7] in 1990; 60·6 million 
[60·1–61·0] in 2017). These factors have led to a rapidly 
changing population structure, with the mean age 
increasing from 38·4 years (35·7–41·0) in 1990 to 
44·4 years (44·1–44·7) in 2017.
In 2017, under-5 and infant mortality in Italy were 
lower than expected on the basis of SDI level (under-5 
mortality: 3·2 deaths per 1 000 livebirths; infant mortality: 
2·7 deaths per 1000 livebirths). Finally, with an HAQ 
Index of 94·9 in 2016, Italy had the ninth highest HAQ 
Index score globally, exceeding the score expected on the 
basis of its SDI value by 0·6.4
For more information on the GBD 
Socio-demographic Index see 
http://ghdx.healthdata.org/
record/ihme-data/gbd-2017-
socio-demographic-index-sdi-
1950%E2%80%932017
For Financial Global Health 
visualisation see https://vizhub.
healthdata.org/fgh/
For GBD Compare see https://
vizhub.healthdata.org/gbd-
compare/
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With an HAQ Index of 81·54, Italy also ranked ninth in 
1990, showing a constant increase from 1990 to 2016 in 
line with the other top 12 countries globally (appendix 
p 1). In Italy in 2015, the overall per capita expenditure for 
health was divided such that 75% was from government 
health spending, 23% was from out-of-pocket spending, 
and 2% was from prepaid private spending. From 
2010 to 2015, government health spending as percentage 
of GDP decreased from 7·0% to 6·7%, while out-of-
pocket spending increased from 1·8% to 2·0%.
The overall number of YLLs decreased by 20·1% from 
1990 to 2017 (table 1), while the total number of deaths 
increased by 14·9% (appendix p 9), indicating that people 
are dying at older ages, closer to their potential life 
expectancy. The overall age-standardised death rate 
decreased by 41·3% between 1990 and 2017, while age-
standardised YLL rates decreased by 49·5% in the same 
period.
Ischaemic heart disease, Alzheimer’s disease and other 
dementias, and stroke are the first, second, and third Level 3 
causes of death and the first, third, and fourth Level 3 
causes of YLLs in 2017 (table 1; appendix p 9). Among 
Level 2 causes, neoplasms are the first leading cause 
of YLLs and deaths, and cardiovascular diseases are the 
second leading cause of YLLs and deaths. Despite the 
overall decrease between 1990 and 2017 in both the number 
of YLLs and age-standardised YLL rate, in 2017 
cardiovascular diseases, which comprise 32% of all YLLs 
in 1990, still accounted for 28% of YLLs (full data for YLLs 
are available online). Also in terms of age-standardised 
death rates, a decrease was seen for both neoplams 
(–28·2%, 95% UI –32·3 to -24·6) and cardiovascular 
diseases (–53·7%, –56·1 to –51·4) between 1990 and 2017.
The second leading cause of Level 3 YLLs in 2017 was 
tracheal, bronchus, and lung cancer (table 1). Taken 
together, among Level 2 causes, neoplasms were the top 
cause of YLLs in 2017, comprising 38% of all YLLs. The 
number of YLLs caused by neoplasms decreased by 
5·9% (95% UI 0·9–11·2) between 1990 and 2017. 
However, significant increases in number of YLLs were 
registered for pancreatic, prostate, kidney, cervical, 
uterine, and skin cancers (data not shown; full YLLs 
Level 2 data are available online).
At the same time, the age-standardised YLL rate 
decreased between 1990 and 2017 for all neoplasms except 
uterine cancer (for all neoplasms –34·3% [95% UI 
–38·2 to –30·8], for uterine cancer 68·6% [47·6% to 92·6]). 
Age-standardised death rates also showed significant 
increases only for uterine cancer (71% increase; from 
0·6 deaths [0·6–0·7] per 100 000 in 1990 to 1·1 deaths 
[1·0–1·2] per 100 000 in 2017). For number of deaths, 
pancreatic cancer had an increase of 65·6% (53·1 to 79·1) 
reaching almost 13 000 deaths in 2017 (appendix p 9), 
whereas uterine cancer, even though the number of 
deaths was lower than for pancreatic cancer (1600 in 2017), 
the number of deaths had increased by 177% (146 to 213) 
since 1990.
Alzheimer’s disease and other dementias became the 
third leading Level 3 cause of YLLs in 2017, increasing 
from sixth in 1990, and accounted for 7% of total YLLs 
(table 1). The number of YLLs due to this cause increased 
by 75·6% between 1990 and 2017, while the number of 
deaths increased by 117·7% (95% UI 104·7 to 129·5) and 
death rates increased by 104·0% (91·9 to 115·2) during 
this period (table 1; appendix p 9). However, age-
standardised rates attributable to this cause decreased 
significantly both for YLLs (–15·0%, –20·7 to –9·6) and 
deaths (–12·6%, –17·9 to –7·6).
Overall, both the number of deaths and YLLs caused 
by road injuries decreased significantly between 1990 
and 2017 (number of deaths in 1990: 11 243 [11 009 to 
11 474]; in 2017: 5710 [95% UI 5333 to 6090]; percentage 
change in number of deaths –49·2% [–52·5 to –45·6]), 
with a decrease in the age-standardised death rate of 
62·1% (–64·6 to –59·2) and shifted in rank from 12th to 
23rd as a cause of death. YLLs decreased by 66·3% 
[–68·5 to –63·6]), from 470 389 (460 429 to 480 378) in 
1990 to 158 685 (147 495 to 170 172) in 2017, shifting from 
fourth to 14th as a cause of YLLs.
The ranking of diabetes for number of YLLs did not 
vary substantially (tenth in 1990 to eighth in 2017), with a 
decrease of 16·1% (–22·8 to –9·4) in absolute numbers 
and a decrease of 46·9% (–51·1 to –42·5) in age-
standardised YLL rate (table 1). The number of deaths 
caused by diabetes increased by 12·2% (3·2 to 21·3) 
between 1990 and 2017, even though the age-standardised 
death rate decreased by 40·5% (–45·1 to –35·8; 
appendix p 9).
The rank of chronic kidney disease by number of YLLs 
increased from 20th to 16th and by deaths increased from 
15th to ninth between 1990 and 2017 (table 1; appendix 
p 9). During this period, the total number of deaths from 
chronic kidney disease increased by 74·2% (95% UI 61·1 
to 89·2), while age-standardised death rates decreased 
by 19·5% (–25·3 to –12·9; from 9·1 [8·8–9·4] per 
100 000 population to 7·3 [6·8–7·9] per 100 000 population). 
Drug use disorders had a decrease in the number of 
deaths of 35·4% (–43·4 to –26·9), with the number of 
YLLs decreasing even more (–62·5% [–68·0 to –55·9]), 
but still being responsible for 147 000 DALYs (111 000 to 
184 000).
Finally, the ranking of neonatal disorders (including 
preterm births, encephalopathies due to birth asphyxia 
and trauma, sepsis and other infections, haemolytic 
diseases and other neonatal jaundice, and other 
neonatal disorders) decreased significantly in terms of 
the number of YLLs, from 13th with 250 959 YLLs in 
1990, to 32nd with 63 501 YLLs in 2017 (–74·7% [–67·3 to 
–80·8]).
Even in terms of number of deaths, a considerable 
reduction was seen from 2857 in 1990 to 723 in 2017. This 
reduction was coupled with a significant reduction in 
YLLs caused by congenital defects, reflected in a decrease 
of 63·9% (95% UI –50·5 to –70·0) in the number of 
See Online for appendix
For full YLLs data and YLLs data 
at Level 2 see https://vizhub.
healthdata.org/gbd-compare/
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YLLs, and a decrease of 55·5% (–42·7 to –62·8) in the 
number of deaths. These results are only partially 
explained by a reduction in the number of livebirths, 
which decreased from 569 255 in 1990 to 458 151 in 
2017, an almost 20% decrease (full data are available on 
the Istat website).
For YLDs, the ranking of the most prevalent diseases 
and injuries (not discussed here) is shown in the appendix 
(p 10), and the leading causes of YLDs for 2017 and a 
comparison with 1990 is shown in table 2;. Between 
1990 and 2017, the number of YLDs increased by 
17·6% (95% UI 15·7 to 19·5) but the age-standardised YLD 
Rank of cause of YLLs YLLs (in thousands) All-age YLL rate per 100 000 people Age-standardised YLL rate per 
100 000 people
1990 2017 2017 Percentage 
change 
1990–2017
2017 Percentage 
change 
1990–2017
2017 Percentage 
change 
1990–2017
All causes ·· ·· 8005 
(7615 to 8403)
–20·1% 
(–23·9 to –16·3)
13 209 
(12 566 to 13 866)
–25·1% 
(–28·6 to –21·5)
6709 
(6384 to 7038)
–49·5% 
(–52·0 to –47·1)
Ischaemic heart 
disease
1 
(1 to 1)
1 
(1 to 1)
1028 
(957 to 1118)
–35·3% 
(–39·5 to –30·4)
1697 
(1579 to 1845)
–39·3% 
(–43·3 to –34·8)
690 
(640 to 743)
–60·9% 
(–63·6 to –58·0)
Tracheal, 
bronchus, and 
lung cancer
3 
(3 to 3)
2 
(2 to 2)
602 
(564 to 645)
–15·5% 
(–21·3 to –9·4)
994 
(931 to 1064)
–20·8% 
(–26·2 to –15·0)
479 
(449 to 512)
–41·2% 
(–45·2 to –37·1)
Alzheimer’s 
disease and other 
dementias
6 
(6 to 6)
3 
(3 to 4)
581 
(542 to 619)
75·6% 
(64·2 to 86·1)
959 
(895 to 1022)
64·6% 
(53·9 to 74·5)
302 
(281 to 323)
–15·0% 
(–20·7 to –9·6)
Stroke 2 
(2 to 2)
4 
(3 to 4)
580 
(539 to 640)
–37·7% 
(–42·1 to –32·6)
956 
(889 to 1056)
–41·6% 
(–45·7 to –36·8)
369 
(343 to 403)
–64·1% 
(–66·7 to –61·3)
Colon and rectum 
cancer
8 
(8 to 8)
5 
(5 to 5)
319 
(295 to 345)
6·2% 
(–1·9 to 14·8)
526 
(486 to 569)
–0·4% 
(–8·1 to 7·6)
245 
(226 to 265)
–28·1% 
(–33·8 to –22·1)
Chronic 
obstructive 
pulmonary disease
11 
(11 to 13)
6 
(6 to 6)
252 
(233 to 274)
–4·7% 
(–12·6 to 5·1)
416 
(385 to 452)
–10·6% 
(–18·1 to –1·5)
153 
(141 to 167)
–45·5% 
(–50·3 to –39·4)
Breast cancer 9 
(9 to 9)
7 
(7 to 7)
240 
(217 to 262)
–12·9% 
(–21·6 to –4·8)
396 
(358 to 433)
–18·4% 
(–26·5 to –10·8)
213 
(192 to 233)
–38·2% 
(–44·3 to –32·4)
Diabetes 10 
(10 to 11)
8 
(8 to 8)
226 
(210 to 243)
–16·1% 
(–22·8 to –9·4)
372 
(346 to 401)
–21·4% 
(–27·6 to –15·1)
155 
(144 to 167)
–46·9% 
(–51·1 to –42·5)
Cirrhosis and 
other chronic liver 
diseases
5 
(5 to 5)
9 
(9 to 10)
214 
(193 to 234)
–47·8% 
(–52·8 to –42·8)
354 
(318 to 387)
–51·1% 
(–55·7 to –46·4)
185 
(166 to 203)
–63·2% 
(–67·0 to –59·4)
Pancreatic cancer 16 
(16 to 17)
10 
(9 to 10)
208 
(194 to 226)
39·3% 
(28·0 to 51·4)
344 
(320 to 374)
30·6% 
(20·0 to 41·9)
163 
(151 to 177)
–3·8% 
(–11·3 to 4·5)
Stomach cancer 7 
(7 to 7)
11 
(11 to 12)
185 
(172 to 200)
–42·9% 
(–47·2 to –38·5)
306 
(284 to 329)
–46·5% 
(–50·5 to –42·4)
144 
(133 to 155)
–60·8% 
(–63·9 to –57·7)
Hypertensive 
heart disease
19 
(19 to 25)
12 
(11 to 20)
184 
(86 to 211)
44·3% 
(–17·9 to 64·1)
304 
(141 to 349)
35·3% 
(–23·1 to 53·9)
105 
(58 to 119)
–22·9% 
(–50·8 to –13·3)
Liver cancer 15 
(15 to 15)
13 
(12 to 13)
179 
(162 to 199)
–1·2% 
(–10·8 to 9·3)
296 
(267 to 328)
–7·4% 
(–16·4 to 2·4)
141 
(127 to 157)
–30·9% 
(–37·7 to –23·5)
Road injuries 4 
(4 to 4)
14 
(13 to 15)
159 
(147 to 170)
–66·3% 
(–68·5 to –63·6)
262 
(243 to 281)
–68·4% 
(–70·5 to –65·9)
264 
(246 to 284)
–67·1% 
(–69·5 to –64·5)
Lower respiratory 
infections
22 
(20 to 22)
15 
(15 to 16)
140 
(129 to 152)
21·4% 
(9·9 to 33·3)
231 
(213 to 251)
13·8% 
(3·0 to 25·0)
108 
(100 to 117)
–41·8% 
(–48·5 to –35·0)
Chronic kidney 
disease
20 
(18 to 20)
16 
(14 to 17)
139 
(129 to 150)
12·3% 
(4·1 to 22·0)
230 
(214 to 247)
5·3% 
(–2·4 to 14·3)
89 
(83 to 96)
–37·4% 
(–42·0 to –32·1)
Self-harm 14 
(14 to 14)
17 
(16 to 18)
137 
(126 to 150)
–27·1% 
(–33·4 to –19·9)
226 
(208 to 247)
–31·6% 
(–37·6 to –24·9)
192 
(177 to 210)
–32·3% 
(–38·3 to –25·7)
Leukaemia 18 
(17 to 18)
18 
(17 to 19)
132 
(122 to 142)
–9·6% 
(–16·7 to –2·3)
217 
(201 to 235)
–15·3% 
(–22·0 to –8·4)
137 
(126 to 149)
–36·2% 
(–41·7 to –30·2)
Prostate cancer 27 
(23 to 28)
19 
(14 to 18)
114 
(97 to 179)
23·7% 
(7·0 to 62·7)
189 
(161 to 295)
16·0% 
(0·3 to 52·5)
72 
(61 to 116)
–24·2% 
(–35·0 to 1·2)
Other malignant 
neoplasms
21 
(21 to 24)
20 
(21 to 22)
100 
(83 to 113)
–14·4% 
(–24·4 to 10·5)
165 
(137 to 186)
–19·8% 
(–29·2 to 3·5)
107 
(89 to 124)
–34·4% 
(–43·4 to –13·3)
Data in parentheses are 95% uncertainty intervals. YLLs=years of life lost.
Table 1: Number of YLLs by Level 3 causes in 1990 and 2017, and YLL rates and age-standardised YLL rates for 2017 with percentage change between 
1990 and 2017, ordered by ranking of top 20 causes of YLLs in 2017
For 1990 data see http://
seriestoriche.istat.it/fileadmin/
documenti/Tavola_2.6.1.xls
For 2017 data see https://www.
istat.it/it/files//2018/11/Report_
Natalita_fecondita.pdf
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rate decreased by 2·8% (–4·4 to –1·1). Low back pain was 
the leading cause of YLDs for 2017. Age-standardised YLD 
rates for low back pain decreased significantly between 
1990 and 2017 (–6·2%, –11·1 to –1·1), although the number 
of YLDs increased significantly (11·2%, 5·0 to 17·3).
In the 15–49 years age group, low back pain and 
headache disorders were the leading causes of YLDs in 
the in both 1990 and 2017, with non-significant changes 
in YLD rates since 1990 (low back pain, percentage 
change: –0·10% [–0·90 to 0·07]; headache disorders, 
percentage change: 0·04% [–0·01 to 0·08]; full data are 
available online).
In 2017, diabetes was the third leading cause in number 
of YLDs, with an increase of 89·4% (95% UI 69·6 to 116·1) 
Rank of cause of 
YLDs
YLDs (in thousands) YLD rate per 100 000 people Age-standardised YLD rate per 
100 000 people
1990 2017 2017 Percentage 
change, 
1990–2017
2017 Percentage 
change, 
1990–2017
2017 Percentage 
change, 
1990–2017
All causes ·· ·· 8488 
(6369 to 10 878)
17·6% 
(15·7 to 19·5)
14 008 
(10 510 to 17 951)
10·2% 
(8·5 to 12·0)
10 313 
(7684 to 13 277)
–2·8% 
(–4·4 to –1·1)
Low back pain 1 
(1 to 1)
1 
(1 to 1)
1057 
(758 to 1421)
11·2% 
(5·0 to 17·3)
1744 
(1251 to 2345)
4·2% 
(–1·5 to 9·9)
1284 
(917 to 1733)
–6·2% 
(–11·1 to –1·1)
Headache 
disorders
2 
(2 to 2)
2 
(2 to 2)
723 
(477 to 1035)
4·5% 
(1·1 to 8·2)
1194 
(787 to 1708)
–2·0% 
(–5·2 to 1·4)
1110 
(730 to 1598)
0·6% 
(–2·5 to 3·9)
Diabetes 8 
(8 to 8)
3 
(3 to 3)
507 
(343 to 697)
89·4% 
(69·6 to 116·1)
838 
(566 to 1151)
77·5% 
(59·0 to 102·5)
446 
(299·9 to 623)
38·2% 
(24·5 to 55·8)
Neck pain 4 
(4 to 4)
4 
(4 to 4)
443 
(309 to 620)
25·3% 
(21·9 to 28·9)
731 
(510 to 1024)
17·4% 
(14·3 to 20·8)
481 
(336 to 667)
–0·1% 
(–1·7 to 1·9)
Age-related and 
other hearing loss
6 
(6 to 7)
5 
(5 to 5)
427 
(300 to 588)
54·8% 
(50·3 to 60·2)
705 
(495 to 971)
45·1% 
(40·9 to 50·2)
328 
(225 to 460)
0·2% 
(–2·0 to 2·3)
Depressive 
disorders
3 
(3 to 3)
6 
(6 to 6)
383 
(270 to 519)
–1·7% 
(–6·7 to 3·3)
632 
(446 to 856)
–7·9% 
(–12·6 to –3·2)
528 
(372 to 726)
–10·8% 
(–15·0 to –6·2)
Falls 7 
(6 to 7)
7 
(7 to 7)
334 
(237 to 456)
23·7% 
(20·1 to 27·9)
551 
(392 to 752)
15·9% 
(12·6 to 19·9)
354 
(249 to 487)
–7·8% 
(–9·9 to –5·5)
Anxiety disorders 5 
(5 to 5)
8 
(8 to 8)
319 
(224 to 423)
2·0% 
(–3·4 to 7·9)
526 
(370 to 699)
–4·4% 
(–9·4 to 1·2)
499 
(351 to 667)
–2·6% 
(–8·0 to 3·2)
Other 
musculoskeletal 
disorders
9 
(9 to 9)
9 
(9 to 9)
251 
(164 to 362)
26·7% 
(14·3 to 40·9)
414 
(270 to 598)
18·7% 
(7·2 to 32·1)
313 
(208 to 448)
9·8% 
(0·7 to 20·7)
Blindness and 
vision impairment
11 
(10 to 11)
10 
(11 to 11)
215 
(149 to 294)
28·0% 
(24·3 to 32·2)
354 
(245 to 486)
20·0% 
(16·5 to 23·9)
200 
(135 to 282)
–10·6% 
(–13·3 to –7·9)
Chronic 
obstructive 
pulmonary disease
13 
(12 to 19)
11 
(10 to 14)
187 
(155 to 221)
46·9% 
(30·1 to 63·7)
308 
(256 to 365)
37·7% 
(21·9 to 53·4)
151 
(124 to 180)
0·9% 
(–10·3 to 11·8)
Alzheimer’s 
disease and other 
dementias
22 
(19 to 22)
12 
(12 to 13)
178 
(129 to 231)
85·7% 
(70·5 to 102·9)
294 
(213 to 381)
74·1% 
(59·8 to 90·2)
93 
(67 to 121)
–9·5% 
(–16·4 to –1·7)
Oral disorders 10 
(10 to 11)
13 
(12 to 13)
172 
(107 to 261)
–2·3% 
(–4·5 to 0·0)
285 
(176 to 430)
–8·4% 
(–10·5 to –6·3)
182 
(109·7 to 280)
–21·2% 
(–24·0 to –18·9)
Osteoarthritis 20 
(12 to 29)
14 
(10 to 20)
148 
(75 to 295)
51·8% 
(45·0 to 58·4)
245 
(123 to 487)
42·3% 
(35·9 to 48·5)
116 
(58 to 231)
4·0% 
(–0·5 to 8·5)
Drug use 
disorders
12 
(13 to 13)
15 
(14 to 17)
124 
(89 to 162)
–11·0% 
(–18·6 to –2·1)
205 
(147 to 268)
–16·5% 
(–23·7 to –8·3)
223 
(158 to 291)
–4·7% 
(–13·5 to 5·5)
Stroke 15 
(16 to 20)
16 
(15 to 22)
121 
(87 to 154)
5·8% 
(–3·7 to 15·0)
200 
(144 to 254)
–0·8% 
(–9·7 to 7·8)
89 
(65 to 114)
–31·0% 
(–36·3 to –25·7)
Bipolar disorder 16 
(14 to 17)
17 
(16 to 21)
117 
(73 to 173)
2·4% 
(–4·9 to 10·3)
193 
(120 to 285)
–4·0% 
(–10·8 to 3·3)
179 
(110 to 268)
–0·7% 
(–8·0 to 7·8)
Road injuries 14 
(15 to 15)
18 
(17 to 19)
116 
(83 to 157)
–2·6% 
(–4·5 to –0·6)
192 
(137 to 259)
–8·7% 
(–10·5 to –6·8)
131 
(93 to 177)
–21·3% 
(–22·9 to –19·6)
Neonatal 
disorders
17 
(14 to 18)
19 
(16 to 20)
115 
(83 to 157)
2·3% 
(–9·8 to 15·7)
190 
(137 to 259)
–4·1% 
(–15·4 to 8·5)
226 
(162 to 308)
3·1% 
(–9·4 to 17·0)
Upper digestive 
system diseases
18 
(16 to 22)
20 
(15 to 23)
114 
(68 to 180)
12·2% 
(6·9 to 16·6)
188 
(112 to 297)
5·1% 
(0·2 to 9·3)
134 
(80 to 215)
–5·8% 
(–9·8 to –2·5)
Data in parentheses are 95% uncertainty intervals. YLDs= years lived with disability.
Table 2: Number of YLDs, YLD rates and age-standardised YLD rates in 2017 with percentage change between 1990 and 2017, ordered by ranking of 
top 20 Level 3 causes of YLDs in 2017
For more YLDs data see https://
vizhub.healthdata.org/gbd-
compare/
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since 1990 in terms of absolute numbers and 
38·2% (24·5 to 55·8) in terms of age-standardised rates 
(table 2). Alzheimer’s disease and other dementias 
ranked 12th in terms of number of YLDs, with an 
85·7% (70·5 to 102·9) increase in the number of YLDs 
between 1990 and 2017, even while the age-standardised 
YLD rate decreased by 9·5% (–16·4 to –1·7).
In 2017, if considered together (ie, at Level 2), muscu-
loskeletal disorders were the most important cause of 
YLDs, followed by mental disorders and neurological 
disorders (figure 1). The prevalence of cardiovascular 
diseases, skin and subcutaneous diseases, and 
sense organ diseases appear to increase with age, 
whereas nutritional deficiencies, enteric infections, 
other infectious diseases, and other non-communicable 
diseases occur more often in younger age groups. YLDs 
due to musculoskeletal disorders and mental disorders 
increase with age up to 50–54 years, and then appear to 
gradually decrease. Number of YLDs due to neoplasms 
increased by 68·2% (95% UI 82·5–55·9).
For DALYs, in 1990 the YLD component made up 
42% of all DALYs, reaching 51% in 2017, which is 
primarily due to a 20·1% decrease in YLLs between 1990 
and 2017 and a 17·6% increase in YLDs over the same 
period. As a result, the disease and injuries that 
contribute the most to YLLS and YLDs contribute 
substantially to national DALYs.
In 2017, ischaemic heart disease, as the the leading 
cause of YLLs, was the top contributor to premature 
death and the leading cause of DALYs, followed by low 
back pain, the top contributor to non-fatal disability. 
Alzheimer’s disease and other dementias was third 
highest contributor and diabetes was fourth highest 
contributor to DALYs (figure 2, table 3).
The fifth leading cause of DALYs was headache 
disorders, in this case exclusively to non-fatal diseases 
(in GBD, headache disorders are only counted in terms 
of disability, not mortality). DALYs caused by road 
injuries decreased by 53·4% (95% UI –57·2 to –49·5) 
between 1990 and 2017. Significant reductions were also 
seen in DALYs caused by stroke; tracheal, bronchus, and 
lung cancer; stomach cancer; cirrhosis and other 
chronic liver diseases; neonatal disorders and congenital 
birth defects; self-harm; and cardiomyopathy and 
myocarditis (figure 2). All these causes also decreased 
significantly during this period in terms of age-
standardised DALY rates (table 3; full data for DALY rates 
are available online, suggesting that these reductions 
reflect an actual health improvement for these causes 
not only for the population as a whole, but also for 
specific age groups.
The largest increases in number of DALYs (table 3) 
from 1990 to 2017 were seen for Alzheimer’s disease 
and other dementias (77·9%), age-related hearing loss 
(54·8%), and hypertensive heart disease (45·1%). How-
ever, age-standardised DALY rates decreased slightly 
for both Alzheimer’s disease and other dementias 
(percentage change –13·8%, 95% UI –18·4 to –9·1) and 
Figure 1: Number of YLDs for 22 Level 2 diseases and injuries in Italy in 2017, for both sexes combined, by age group
YLDs=years lived with disability.
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hypertensive heart diseases (–21·1%, –44·5 to –12·5), 
while age-related hearing loss had no change 
(0·2%, –2·0 to 2·3). Even if not in the top 20 causes by 
number of DALYs, an increase of 39·7% (28·4 to 51·7) 
was seen in DALYs due to pancreatic cancer (from 
151 000 DALYs in 1990 to 196 000 DALYs in 2017), and of 
164·7% (129·7 to 202·5) was seen for DALYs due to 
uterine cancer (from 13 100 to 34 600 DALYs). For 
neoplasms (Level 2), the age-standardised DALY rate 
decreased by 32·5% (–28·7 to –36·4%) from 1990 to 
2017, with the number of DALYs staying almost the same 
(3·32 million in 1990 and 3·20 million in 2017).
For deaths and DALYs attributable to risk factors, the 
percentage of DALYs and the number of deaths for the 
top 20 risk factors in 2017 by Level 2 causes are shown in 
the appendix (pp 3–4).
Smoking was the main cause of DALYs and was 
associated particularly with neoplasms and cardiovascular 
diseases. High-fasting plasma glucose concentration)18 
was the second leading risk factor for DALYs, associated 
with diabetes and kidney diseases and cardiovascular 
diseases.
The third leading risk factor was high systolic blood 
pressure, the main cause of cardiovascular diseases. In 
terms of number of deaths, high blood pressure was the 
top attributable risk factor, followed by high fasting 
plasma glucose and smoking. High body-mass index 
(BMI) was the fourth leading attributable risk factor for 
both number of DALYs and number of deaths.
Potentially modifiable behaviours and metabolic 
risks—also associated with modifiable behaviours—
have a major role in risk of mortality and DALYs. 
Among the top 15 risk factors for DALYs, eight are 
behavioural risks (eg, smoking, alcohol use, and diet 
low in whole grains) and three are metabolic risks that 
are closely linked with behaviours (eg, high BMI; 
appendix pp 3–4). These risk factors affect deaths 
and DALYs due to cardiovascular diseases, neoplasms, 
diabetes and kidney diseases, lower respiratory infec-
tions, and liver diseases.
Of 181 000 deaths (95% UI 171 000 to 190 000) due to 
cancer in 2017, 44 400 (41 200 to 47 800) were attributable 
to smoking, 12 000 (9600 to 14 800) to alcohol use, and 
9500 (5400 to 14 200) to high BMI. Of 217 000 deaths 
(207 000 to 227 000) in 2017 casued by cardiovascular 
disease, 109 900 (92 700 to 126 800) were attributed to 
high systolic blood pressure, 47 600 (31 100 to 65 700) to 
high LDL cholesterol, 28 700 (19 700 to 38 500) to diet low 
Figure 2: Top 25 causes of DALYs in Italy, in 1990–2017, and percentage change between 1990 and 2017
Dotted lines show a decrease in rank and solid lines show an increase in rank. DALYs=disability-adjusted life-years.
1 Ischaemic heart disease
2 Stroke
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4 Tracheal, bronchus, and lung cancer
5 Headache disorders
6 Road injuries
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1 Ischaemic heart disease
2 Low back pain
3 Alzheimer's disease and other dementias
4 Diabetes 
5 Headache disorders
6 Stroke
7 Tracheal, bronchus, and lung cancer
8 Neck pain
9 Chronic obstructive pulmonary disease
10 Age-related and other hearing loss
11 Falls
12 Depressive disorders
13 Colon and rectum cancer
14 Anxiety disorders
15 Breast cancer
16 Road injuries
17 Other musculoskeletal disorders
18 Cirrhosis and other chronic liver diseases
19 Hypertensive heart disease
20 Blindness and vision impairment
21 Pancreatic cancer
22 Chronic kidney disease
23 Stomach cancer
24 Liver cancer
25 Neonatal disorders
29 Congenital birth defects
30 Drug use disorders
31 Self-harm
42 Cardiomyopathy and myocarditis
Percentage change in number 
of all-age DALYs
Leading causes (2017)Leading causes (1990)
Communicable, maternal, neonatal, and nutritional diseases
Non-communicable diseases
Injuries
 –33·6% (–37·8 to –29·0)
 11·2% (5·0 to 17·3)
 77·9% (68·4 to 87·2)
 36·6% (23·1 to 50·4)
 4·5% (1·1 to 8·2)
 –32·9% (–37·1 to –28·2)
 –14·9% (–20·7 to –8·8)
 25·3% (21·9 to 28·9)
 12·1% (3·8 to 20·6)
 54·8% (50·3 to 60·2)
 11·9% (7·3 to 15·8)
 –1·7% (–6·7 to 3·3)
 9·7% (1·1 to 18·6)
 2·0% (–3·4 to 7·9)
 –8·3% (–17·4 to 0·4)
 –53·4% (–57·2 to –49·5)
 27·6% (15·7 to 40·9)
 –43·1% (–48·1 to –38·1)
 45·1% (–7·6 to 62·4)
 28·0% (24·3 to 32·2)
 39·7% (28·4 to 51·7) 
 16·1% (8·7 to 24·1) 
 –42·2% (–46·6 to –37·7) 
 –0·6% (–10·2 to 10·1) 
 –50·8% (–58·7 to –42·6) 
 –37·9% (–45·7 to 27·1) 
 –26·3% (–33·1 to –19·8) 
 –25·5% (–31·6 to –18·7) 
 –62·8% (–67·2 to 49·4) 
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in whole grains, and 15 900 (8500 to 24 900) to low 
physical activity.
When combined, dietary risks were the third leading risk 
factor for deaths in 2017, after high blood pressure and 
high fasting plasma glucose concentration; and the fourth 
for DALYs after tobacco consumption (eg, chewing), high 
fasting plasma glucose concentration, and high blood 
pressure. Dietary risks are a cause of cardiovascular 
diseases, neoplasms, diabetes, and kidney diseases. 
Among the top ten attributable Level 3 risk factors for 
Rank by number of 
DALYs in 2017
DALYs (in thousands) All-age DALY rate per 
100 000 people
Age-standardised DALY rate per 
100 000 people
1990 2017 2017 Percentage 
change, 
1990–2017
2017 Percentage 
change, 
1990–2017
2017 Percentage 
change, 
1990–2017
All causes ·· ·· 16 493 
(14 334 to 18 969)
–4·3% 
(–7·9 to –0·9)
27 217 
(23 654 to 31 303)
–10·3% 
(–13·6 to –7·1)
17 022 
(14 382 to 20 024)
–28·8% 
(–32·5 to –25·3)
Ischaemic heart 
disease
1 
(1 to 1)
1 
(1 to 2)
1110 
(1034 to 1204)
–33·6% 
(–37·8 to –29·0)
1831 
(1706 to 1987)
–37·8% 
(–41·7 to –33·4)
749 
(697 to 805)
–59·7% 
(–62·3 to –56·9)
Low back pain 3 
(2 to 4)
2 
(1 to 2)
1057 
(758 to 1421)
11·2% 
(5·0 to 17·3)
1744 
(1251 to 2345)
4·2% 
(–1·5 to 9·9)
1284 
(917 to 1733)
–6·2% 
(–11 to –1·1)
Alzheimer’s 
disease and other 
dementias
9 
(9 to 11)
3 
(3 to 5)
759 
(695 to 825)
77·9% 
(68·4 to 87·2)
1253 
(1148 to 1362)
66·7% 
(57·9 to 75·4)
396 
(362 to 429)
–13·8% 
(–18·4 to –9·1)
Diabetes 7 
(6 to 7)
4 
(4 to 6)
733 
(570 to 921)
36·6% 
(23·1 to 50·4)
1210 
(941 to 1520)
28·0% 
(15·4 to 41·0)
601 
(457 to 777)
–2·2% 
(–12·8 to 8·1)
Headache 
disorders
5 
(4 to 6)
5 
(3 to 7)
723 
(477 to 1035)
4·5% 
(1·1 to 8·2)
1194 
(787 to 1708)
–2·0% 
(–5·2 to 1·4)
1110 
(730 to 1598)
0·6% 
(–2·5 to 3·9)
Stroke 2 
(2 to 3)
6 
(4 to 6)
700 
(647 to 764)
–32·9% 
(–37·1 to –28·2)
1156 
(1068 to 1261)
–37·1% 
(–41·0 to –32·7)
458 
(422 to 498)
–60·4% 
(–62·9 to –57·8)
Tracheal, 
bronchus, and 
lung cancer
4 
(3 to 5)
7 
(5 to 7)
612 
(573 to 654)
–14·9% 
(–20·7 to –8·8)
1011 
(946 to 1079)
–20·2% 
(–25·7 to –14·6)
487 
(456 to 520)
–40·9% 
(–44·9 to –36·6)
Neck pain 14 
(9 to 17)
8 
(8 to 11)
443 
(309 to 620)
25·3% 
(21·9 to 28·9)
731 
(510 to 1024)
17·4% 
(14·3 to 20·8)
481 
(336 to 667)
–0·1% 
(–1·7 to 1·9)
Chronic 
obstructive 
pulmonary disease
10 
(10 to 13)
9 
(8 to 12)
438 
(399 to 477)
12·1% 
(3·8 to 20·6)
723 
(658 to 788)
5·0% 
(–2·7 to 13·1)
304 
(273 to 335)
–29·4% 
(–35 to –23·7)
Age-related and 
other hearing loss
20 
(16 to 21)
10 
(9 to 12)
427 
(300 to 588)
54·8% 
(50·3 to 60·2)
705 
(495 to 971)
45·1% 
(40·9 to 50·2)
328 
(225 to 460)
0·2% 
(–2·0 to 2·3)
Falls 12 
(10 to 14)
11 
(9 to 10)
418 
(321 to 542)
11·9% 
(7·3 to 15·8)
690 
(529 to 894)
4·9% 
(0·6 to 8·6)
422 
(318 to 554)
–19·2% 
(–23·1 to –16·1)
Depressive 
disorders
11 
(8 to 16)
12 
(11 to 13)
383 
(270 to 519)
–1·7% 
(–6·7 to 3·3)
632 
(446 to 856)
–7·9% 
(–12·6 to –3·2)
528 
(372 to 726)
–10·8% 
(–15·0 to –6·2)
Colon and rectum 
cancer
16 
(13 to 18)
13 
(10 to 15)
345 
(319 to 376)
9·7% 
(1·1 to 18·6)
570 
(526 to 621)
2·8% 
(–5·2 to 11·2)
265 
(244 to 289)
–25·9% 
(–31·7 to –19·6)
Anxiety disorders 17 
(14 to 18)
14 
(13 to 16)
319 
(224 to 423)
2·0% 
(–3·4 to 7·9)
526 
(370 to 699)
–4·4% 
(–9·4 to 1·2)
499 
(351 to 667)
–2·6% 
(–8·0 to 3·2)
Breast cancer 18 
(15 to 19)
15 
(14 to 17)
276 
(248 to 304)
–8·3% 
(–17·4 to 0·4)
456 
(410 to 503)
–14·0% 
(–22·6 to –5·9)
245 
(219 to 271)
–34·9% 
(–41·4 to –28·4)
Road injuries 6 
(5 to 7)
16 
(15 to 16)
275 
(241 to 316)
–53·4% 
(–57·2 to –49·5)
454 
(398 to 522)
–56·3% 
(–59·8 to –52·7)
396 
(354 to 447)
–59·3% 
(–62·1 to –56·2)
Other 
musculoskeletal 
disorders
22 
(21 to 28)
17 
(14 to 20)
266 
(180 to 378)
27·6% 
(15·7 to 40·9)
440 
(297 to 624)
19·6% 
(8·5 to 32·0)
327 
(223 to 463)
9·3% 
(0·6 to 19·1)
Cirrhosis and 
other chronic liver 
diseases
8 
(8 to 12)
18 
(17 to 20)
247 
(223 to 270)
–43·1% 
(–48·1 to –38·1)
407 
(368 to 446)
–46·7% 
(–51·3 to –42·0)
221 
(198 to 243)
–58·6% 
(–62·5 to –54·8)
Hypertensive 
heart disease
30 
(30 to 32)
19 
(22 to 29)
218 
(122 to 250)
45·1% 
(–7·6 to 62·4)
360 
(201 to 412)
36·0% 
(–13·4 to 52·2)
127 
(79 to 143)
–21·1% 
(–44·5 to –12·5)
Blindness and 
vision impairment
28 
(25 to 29)
20 
(19 to 23)
215 
(149 to 294)
28·0% 
(24·3 to 32·2)
354 
(245 to 486)
20·0% 
(16·5 to 23·9)
199·7 
(135 to 282)
–10·6% 
(–13·3 to –7·9)
Data in parentheses are 95% uncertainty intervals. DALYs=disability-adjusted life-years.
Table 3: DALYs, DALY rates, and age-standardised DALY rates in 2017, with percentage change between 1990 and 2017, ordered by ranking in top 20 
Level 3 causes of DALYs in 2017
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DALYs in 2017, five decreased signficantly between 1990 
and 2017 (alcohol use, –58·0%, [95% UI –73·9 to –38·1]; 
high LDL cholesterol, –40·1% [–47·0 to –33·6]; high 
systolic blood pressure, –34·1% [–38·2 to –30·1]; smoking, 
–30·3% [–35·0 to –25·6]; and diet low in whole grains, 
–28·5% [–34·7 to –21·7]; full data on risk factors for DALYs 
are available online), while six did not vary signficantly 
(high fasting plasma glucose concentration, high BMI, 
diet low in whole grains, particulate matter pollution, 
impaired kidney function, and drug use; data not shown). 
For some risk factors, variations over time were not 
significant due to wide UIs, mainly attributable to the lack 
of sufficient evidence. For example, diet high in sugar-
sweetened beverages is responsible for an average, but 
non-significant decrease of 12·2% (95% UI –43·5 to 83·6) 
in attributable number of DALYs.
When comparing the burden of disease among the 
EU15 countries, Italy’s ranking improved between 
1990 and 2017 in terms of both YLLs and YLDs (appendix 
pp 5–6), and globally (appendix pp 11–12). In 2017, Italy 
had the fifth lowest age-standardised death rate in the 
world (first lowest in the EU15), an improvement of ten 
positions since 1990. Italy had the fourth lowest age-
standardised YLL rate in the world in 2017 (first lowest in 
the EU15; an improvement from tenth lowest globally in 
1990) and the 48th lowest age-standardised YLD rate 
(third in the EU15; an improvement from 50th lowest 
globally in 1990).
In the ranking of the main causes of age-standardised 
YLLs (appendix p 5), in Italy, lower respiratory infections, 
chronic obstructive pulmonary disease (COPD), prostate 
cancer, and self-harm ranked better than the avergae of 
the other EU15 countries, while hypertensive heart 
disease, liver cancer, stomach cancer, and diabetes (both 
type 1 and 2; data not shown) ranked worse than the 
avergae of the other EU15 countries.
Compared with the other EU15 countries, in 2017 Italy 
had significantly lower age-standardised DALY rates due to 
self-harm, COPD, and cirrhosis and other chronic liver 
diseases and did not have significantly worse rates than 
any of the other EU15 countries for any diseases or injuries 
in Italy’s top 25 causes of DALYs (appendix p 6). Out of the 
EU15 countries, Italy had the highest age-standardised 
DALY rate for sense organ diseases (including blindness 
and vision impairment, and age-related and other hearing 
loss) and for other musculoskeletal disorders (inferred 
from data in the appendix [p 6]). With respect to life 
expectancy at birth Italy ranked first, and for HALE at birth 
it ranked second among all the EU15 countries in 2017 
(table 4), and it ranked third for life expectancy at birth and 
fourth for HALE at birth globally (data not shown).
In terms of life expectancy and HALE at age 65 years, in 
2017 Italy ranked third highest among the EU15, just after 
France and Spain, and seventh for life expectancy and 
eighth for HALE globally (data not shown). In 2017, life 
expectancy in Italy at age 65 years was 21·0 years (95% UI 
20·7–21·3), an increase of more than 3·5 years compared 
with 1990 (table 4).
Looking at risk factor categories attributed to DALYs, a 
similar distribution is seen for Italy as for the other EU15 
countries (appendix p7). Magnitude and time trends of 
the burden attributable to the three main Level 1 
categories of risk (environmental and occupational, 
behavioural, metabolic), in terms of DALY rates, are 
similar between Italy and the average of the EU15 
countries (appendix p 8), with slightly higher than 
Life expectancy HALE
At birth At age 65 years At birth At age 65 years
1990 2017 1990 2017 1990 2017 1990 2017
Austria 75·8 (75·7–75·9) 81·8 (81·3–82·2) 16·6 (16·5–16·6) 20·2 (19·8–20·5) 66·0 (63·2–68·5) 70·4 (67·2–73·3) 12·6 (11·4–13·6) 15·1 (13·7–16·4)
Belgium 76·0 (76·0–76·1) 81·4 (80·9–81·8) 16·6 (16·5–16·6) 20·1 (19·7–20·4) 65·9 (63·0–68·4) 69·6 (66·2–72·5) 12·4 (11·3–13·4) 14·8 (13·3–16·1)
Denmark 75·0 (74·9–75·1) 80·8 (80·2–81·3) 16·1 (16·0–16·1) 19·4 (19·0–19·7) 65·3 (62·4–67·7) 69·6 (66·4–72·4) 12·1 (11·0–13·1) 14·5 (13·2–15·7)
Finland 75·1 (75·0–75·2) 81·4 (80·9–81·9) 16·2 (16·2–16·3) 20·1 (19·7–20·4) 64·9 (62·0–67·5) 69·8 (66·4–72·7) 12·2 (11·1–13·2) 15·0 (13·6–16·3)
France 77·0 (77·0–77·1) 82·8 (82·4–83·3) 17·9 (17·9–17·9) 21·6 (21·3–21·9) 67·2 (64·4–69·7) 71·7 (68·6–74·5) 13·6 (12·5–14·7) 16·4 (15·0–17·7)
Germany 75·5 (75·5–75·6) 80·6 (79·7–81·5) 16·3 (16·3–16·3) 19·4 (18·8–20·0) 65·6 (62·7–68·1) 69·5 (66·3–72·5) 12·3 (11·2–13·2) 14·5 (13·1–15·8)
Greece 77·5 (77·4–77·6) 81·0 (80·5–81·5) 17·3 (17·3–17·4) 19·8 (19·5–20·2) 67·3 (64·4–69·9) 69·9 (66·9–72·6) 13·1 (12·0–14·1) 15·0 (13·7–16·2)
Ireland 74·9 (74·7–75·0) 81·8 (81·4–82·3) 15·2 (15·1–15·2) 20·0 (19·6–20·3) 65·2 (62·4–67·6) 70·4 (67·1–73·1) 11·5 (10·5–12·4) 14·9 (13·5–16·2)
Italy 77·1 (77·0–77·1) 83·2 (82·7–83·6) 17·3 (17·2–17·3) 21·0 (20·7–21·3) 67·0 (64·1–69·5) 71·9 (68·7–74·7) 13·1 (11·9–14·1) 15·9 (14·4–17·2)
Luxembourg 75·4 (75·2–75·6) 81·7 (81·0–82·4) 16·3 (16·2–16·4) 19·9 (19·4–20·4) 64·9 (61·9–67·5) 69·7 (66·3–72·6) 12·0 (10·83–0) 14·6 (13·2–15·9)
Netherlands 77·0 (76·9–77·1) 81·5 (81·0–82·0) 16·9 (16·8–16·9) 19·7 (19·4–20·0) 66·7 (63·8–69·3) 70·2 (66·9–73·0) 12·7 (11·6–13·7) 14·7 (13·4–16·0)
Portugal 74·1 (74·1–74·2) 81·4 (81·0–81·9) 15·8 (15·7–15·8) 20·1 (19·8–20·4) 64·2 (61·2–66·6) 70·1 (66·9–73·0) 11·8 (10·7–12·7) 15·0 (13·6–16·3)
Spain 77·0 (77·0–77·1) 83·1 (82·7–83·5) 17·5 (17·5–17·5) 21·2 (20·9–21·5) 67·2 (64·4–69·6) 72·1 (68·9–74·8) 13·3 (12·2–14·3) 16·2 (14·8–17·4)
Sweden 77·7 (77·6–77·8) 82·5 (82·1–82·9) 17·4 (17·3–17·4) 20·4 (20·1–20·7) 67·4 (64·4–69·9) 70·9 (67·6–73·9) 13·2 (12·1–14·2) 15·3 (13·9–16·6)
UK 75·8 (75·7–75·8) 81·0 (80·9–81·1) 16·1 (16·1–16·1) 19·7 (19·6–19·7) 65·7 (62·9–68·2) 69·3 (66·0–72·1) 12·3 (11·2–13·2) 14·7 (13·3–15·9)
Data are years, with 95% uncertainty intervals in parentheses. HALE=healthy life expectancy.
Table 4: Age-standardised life expectancy and HALE at birth and at age 65 years in 1990 and 2017, both sexes combined, for Italy and selected western European countries (EU15)
For full details on risk factors for 
DALYs see http://ghdx.
healthdata.org/gbd-results-tool
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average levels of metabolic and environmental risks 
compensated by lower levels of behavioural risks. 
Behavioural risks attributable to DALY rates in Italy had 
consistently less of an effect between 1990 and 2017, 
while metabolic, environmental, and occupational risks 
had more of an effect than the average of the GBD region 
of western Europe (appendix p 8). In particular, the 
burden on DALY rates attributable to alcohol use 
decreased in Italy by 60·7% (95% UI –75·6 to –42·0) 
from 1990 to 2017, whereas in western Europe it 
decreased by 37·5% (–46·2 to –28·5).
Discussion
Our analysis of Italy’s burden of disease is the first to 
use the double lens of temporal trends and a comparison 
with other EU15 countries. The analysis of the GBD 2017 
estimates confirm that Italy’s main health indicators are 
among the best in Europe and globally. Life expectancy 
is high and has shown a substantial and consistent 
increase since 1990. The overall positive situation is 
exemplified by a good general lifestyle, with lower than 
average exposure to behavioural risk factors, and a high 
HAQ Index—even higher than expected in terms of 
SDI value.
Italy’s reduction in age-standardised mortality for most 
diseases and very low infant and under-5 mortality 
should be seen as further, and more specific, indicators 
of the efficiency of the health-care system. By contrast, 
the combination of low fertility and a high life expectancy 
have led to a rapid change in the population structure, 
with the mean age of the population increasing from 
39 years in 1990 to 45 years in 2017. The consequences of 
this trend, in terms of an epidemiological shift, are 
already visible on the disease burden. Our analysis of 
rates of deaths, YLLs, YLDs, and DALYs shows an 
increase between 1990 and 2017 for several diseases, risk 
factors, and injuries, accompanied by a general reduction 
in age-standardised rates.
This phenomenon is mainly the consequence of 
improvement in individual health conditions as well as 
an increased overall burden due to population ageing. 
For example, neoplasms, despite a 32·5% decrease in 
age-standardised DALY rates over the study period, have 
remained stable in terms of the number of DALYs, with 
a 68·2% increase in YLDs balanced by a 5·9% decrease 
in YLLs, attributable to better survival rates in 1990 than 
in 2017.
However, the absolute increasing rates of some 
diseases are a cause for concern and require further in-
depth investigation of both causes and consequences to 
better direct health service resources. For instance, 
Alzheimer’s disease and other dementias, which had 
increased YLLs, YLDs, deaths, and DALYs, increased the 
GBD rankings, placing Italy at the highest rates of both 
YLLs and YLDs among the EU15 countries.
Other examples are pancreatic cancer, for which the 
number of deaths has increased by 65·6%, and uterine 
cancer for which the number of deaths has increased by 
177% between 1990 and 2017.
Italy’s DALY burden attributable to lifestyle-dependent 
risk factors of alcohol use, smoking, high systolic blood 
pressure, and high LDL cholesterol has decreased 
significantly. DALYs attributable to high BMI and 
high fasting plasma glucose concentration did not vary 
significantly since 1990, suggesting that primary 
prevention and health promotion have been insufficient 
to tackle these issues. For the factors listed above, the 
trends are in line with the average for western Europe, 
with Italy having a slightly lower attributable burden—
with the exception of alcohol use, for which the reduction 
in Italy has been more substantial than for other EU15 
countries.
The reduction in deaths due to road injuries indicates 
that preventive measures related to driving regulations 
and enforcement, road network efficiency, and effective 
response from emergency services have had a positive 
effect on road safety. Drug use disorders have also 
substantially decreased in terms of number of 
deaths (–35·4%), YLLs (–62·5%), and YLDs (–11·0%), 
likely due in part to the introduction of effective 
awareness-raising drug-related policies.
However, drug use disorders were still responsible for 
147 000 DALYs in 2017. Increased efforts in health 
promotion and prevention interventions are required to 
address the main risk factors for lifestyle-dependent 
diseases. Smoking, high fasting plasma glucose 
concentration, high blood pressure, dietary risks, high 
BMI, and alcohol use are still the main risk factors of 
Italy’s disease burden. Margins for increased investments 
in prevention can be seen if we consider that in Italy in 
2015 the health system spent €87 per capita on preventive 
measures, against €111 in Germany and €155 in the UK.22
Despite Italy being an interesting example of the 
results that can be achieved by a mix of relatively healthy 
lifestyles and a universal health system, two main issues 
require attention. First, the combination of low fertility 
and high life expectancy are contributing to population 
ageing and its consequences on the change in disease 
burden. Second, public health spending has reduced and 
out-of-pocket expenditure has increased, suggesting a 
shift of essential costs from the public to individual 
families.23,24
If we consider the relevant disparities existing in Italy, 
in terms of health outcomes, system performance, and 
GDP, with better outcomes and performance in the 
north than in the south,25 the main limitation of this 
analysis is the unavailability of estimates at subnational 
level. Our future analyses will look at subnational level 
estimates. In this Article we did not do a comprehensive 
comparison between GBD estimates for Italy and Italian 
data; however, this comparative analysis is being done 
and is among the objectives of the Italian GBD Initiative.
GBD estimates are an important resource to drive 
evidence-based planning and their use can further 
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strengthen the thorough analyses already undertaken 
by several groups of experts.23,25–27 Subnational GBD 
estimates will further strengthen their value and help 
analyse regional differences in the distribution of the 
burden and in the provision of care.
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